PRINCETON, N.J., Oct. 9, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has launched the authorized generic cevimeline hydrochloride 30 mg. capsules in the U.S. market, under an agreement with Daiichi Sankyo, Inc.
Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren's syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently distributed by Daiichi Sankyo, Inc. under the brand name Evoxac®. Evoxac® generated total annualized sales of $62.4 million in the U.S. (IMS MAT June 2012).
Bill Winter, Vice President, Trade Sales and Distribution, North America, said, "Ranbaxy is pleased to announce the launch of cevimeline hydrochloride in 30 mg. capsules, as the authorized generic of Evoxac® in the U.S. This launch further underscores Ranbaxy's resolve to bring high quality, affordable generic medicines to the U.S. healthcare system to meet the growing needs of patients and prescribers."
Regarding the launch, Arun Sawhney, CEO and Managing Director of Ranbaxy Laboratories Limited, added, "We welcome the opportunity to launch cevimeline hydrochloride in the U.S. market. This authorized generic form of Evoxac is an excellent example of optimizing operational synergies that exists between Ranbaxy and Daiichi Sankyo, while accelerating our global business efforts. We see a continuing opportunity to leverage our combined strengths of innovation and the manufacture and marketing of affordable, high quality, generic medicines through this collaboration."
Commenting on the launch of an authorized generic of Evoxac, Tsutomu Une, Ph.D. Chairman of Ranbaxy Laboratories Limited, said, "We refer to the strategy of optimizing the diverse assets of both companies as our Hybrid Business Model, that will allow both organizations to effectively seize opportunities across the full pharmaceutical value chain and product life-cycle, by leveraging the R&D and manufacturing of both Daiichi-Sankyo and Ranbaxy. As such, we will continue to reinforce our respective business platforms over the longer term through this hybrid strategy."
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.
* Evoxac® is a registered trademark of Daiichi Sankyo, Inc.
Charles M. Caprariello
Vice President, Corporate Communications
RF Binder Partners Inc.
SOURCE Ranbaxy Pharmaceuticals Inc.